SMN2 and proximal spinal muscular atrophy: Gavrilina et al. used the severe “Burghes” mouse model of SMA to show that selective expression of SMN in the central nervous system (using the prion promoter) rescues this model, but selective expression in skeletal muscle (using the skeletal muscle actin promoter) does not affect disease progression [59].